Stock INMED PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases InMed Pharmaceuticals Inc Deutsche Boerse AG

Equities

CA13764X1069

End-of-day quote Deutsche Boerse AG
Other stock markets
- EUR - Intraday chart for InMed Pharmaceuticals Inc
May. 14 Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M MT
May. 14 InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
InMed Pharmaceuticals : Material Agreement Form 8 K
PU
InMed Pharmaceuticals : INM-901 Drug Candidate in Development for Alzheimer’s Disease
PU
InMed to Present at the Emerging Growth Conference
NE
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
NE
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
NE
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
NE
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
NE
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
NE
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
NE
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
NE
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
NE
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
NE
InMed Announces Results of 2023 Annual General Meeting
NE
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration
NE
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
NE
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
NE
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules
NE
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules
NE
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies
NE
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
NE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INM Stock
  4. Stock
  5. News InMed Pharmaceuticals Inc
  6. Press Releases